In Segment A, individuals will get various doses and schedules of oral ABBV-744 tablet to detect Protected dosing routine. Additional individuals are going to be enrolled at the recognized monotherapy dosign routine. In Section B, members will acquire oral ruxolitinib and ABBV-744 will probably be presented as "increase-on" therapy. In https://herbertw100iue3.vigilwiki.com/user